It’s now possible to go online and mail-order genetic tests that will predict your genetic risk for common diseases. But because the meaning of the genetic risk factors flagged–how they boost risk for disease–is not yet clear, such tests have received major criticism. In many cases, it’s unclear how to use the findings to improve an individual’s health.
A new $31 million project aims to address that issue by revisiting large epidemiological studies encompassing tens of thousands of people whose medical status has already been well documented. Scientists will use previously donated DNA samples to identify 100 different variations in the participants, and then sift through data to clarify how they affect health. The results could have a broad impact on public-health recommendations, such as who would benefit most from additional screening for cancer or diabetes. They could also provide new targets for drug development.
The deluge of data linking specific genes to common diseases comes from new tools that allow scientists to quickly scan the genome for up to a million common genetic variations. In the past two years, these so-called genome-wide association studies have identified more than 300 genetic variants that boost risk for illnesses such as diabetes, arthritis, and Crohn’s disease, a form of inflammatory-bowel disease. By examining the entire genome without bias, scientists have found genes that they never expected would be involved in a particular disease.
“We’re being inundated with [genome-wide association] results, and that’s a good thing,” says James Evans, a professor of genetics and medicine at the University of North Carolina at Chapel Hill and editor in chief of Genetics in Medicine. “But the next step will be the hardest step, and that is figuring out what it means for human health.”
Although genome-wide association studies have shed light on a great number of genetic variations, it’s not clear how these genetic changes boost risk for different diseases. For example, a variation that boosts risk for type 2 diabetes might do so by disrupting part of the insulin regulation pathway, or it might act through some less well understood pathway, such as inflammation. Both of those possibilities could point to a specific molecular pathway to target in the development of novel diabetes drugs.
“We want to try to understand more about [these genes], in terms of how they are related to disease and whether they are really causative,” says Teri Manolio, director of the Office of Population Genomics at the National Human Genome Research Institute, which is sponsoring the new study.
The project will focus on four existing epidemiological studies in which scientists have spent years tracking participants’ medical information, such as blood pressure, medications, lifestyle, and nutrition. The people being studied encompass a broad swath of the United States’ population, including African Americans, Hispanics, American Indians, and Asian and Pacific Islanders. That’s especially important because most genome-wide association studies were done in people of European descent; other groups may carry that variant at different frequencies.
One of the groups under study is the population screened by the National Health and Nutrition Examination Survey, a survey done every year by the Centers for Disease Control, in Atlanta. “It’s meant to be a snapshot of American health at the time the information is collected,” says Dana Crawford, an assistant professor of molecular physiology and biophysics at Vanderbilt University, in Memphis, TN, who is leading one arm of the project. “We have data on pesticide exposure and occupational exposure–it’s a huge opportunity to look at gene-environment interaction.” (Genes have differing effects under different conditions. For example, some studies link pesticide exposure to Parkinson’s disease, but this risk may only be realized in people who possess certain genetic risk factors.)
“I think this kind of effort will be useful because it will cast a wide net looking at the way results [from genome-wide association studies] can be used to improve human health,” says Evans. “Arguably, much of the utility of this knowledge being generated by [these] studies will be at the population level and could have very useful effects on how we practice medicine from the perspective of public health.”
DeepMind’s cofounder: Generative AI is just a phase. What’s next is interactive AI.
“This is a profound moment in the history of technology,” says Mustafa Suleyman.
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
Human-plus-AI solutions mitigate security threats
With the right human oversight, emerging technologies like artificial intelligence can help keep business and customer data secure
Next slide, please: A brief history of the corporate presentation
From million-dollar slide shows to Steve Jobs’s introduction of the iPhone, a bit of show business never hurt plain old business.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.